U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H18F3N3O2
Molecular Weight 377.3603
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LASMIDITAN

SMILES

CN1CCC(CC1)C(=O)C2=CC=CC(NC(=O)C3=C(F)C=C(F)C=C3F)=N2

InChI

InChIKey=XEDHVZKDSYZQBF-UHFFFAOYSA-N
InChI=1S/C19H18F3N3O2/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22/h2-4,9-11H,5-8H2,1H3,(H,23,24,27)

HIDE SMILES / InChI
Molecular Formula C19H18F3N3O2
Molecular Weight 377.3603
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

LASMIDITAN is a serotonin (5-HT) receptor agonist without vasoconstrictor activity, which selectively binds to the 5-HT(1F) receptor subtype. It is under development for the treatment of migraine.

CNS Activity

Originator

Approval Year

2019
339
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2662
 2.1 nM [Ki]
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
322.8 ng/mL
REVIEW
https://pubmed.ncbi.nlm.nih.gov/29563831/
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LASMIDITAN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
394.7 ng/mL
REVIEW
https://pubmed.ncbi.nlm.nih.gov/29563831/
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LASMIDITAN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
526.15 ng/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT03465436
400 mg single, oral
dose: 400 mg
route of administration: oral
experiment type: single
co-administered:
LASMIDITAN unknown
Homo sapiens
population: healthy
age:
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1892 ng × h/mL
REVIEW
https://pubmed.ncbi.nlm.nih.gov/29563831/
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LASMIDITAN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2244 ng × h/mL
REVIEW
https://pubmed.ncbi.nlm.nih.gov/29563831/
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LASMIDITAN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
3189.08 ng*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT03465436
400 mg single, oral
dose: 400 mg
route of administration: oral
experiment type: single
co-administered:
LASMIDITAN unknown
Homo sapiens
population: healthy
age:
sex:
food status:
Doses

Doses

DosePopulationAdverse events​
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
unhealthy, 18-81 years
n = 1265
Health Status: unhealthy
Condition: migraine
Age Group: 18-81 years
Sex: M+F
Population Size: 1265
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
Other AEs: Dizziness, Fatigue...
Other AEs:
Dizziness (15%)
Fatigue (5%)
Paresthesia (7%)
Sedation (6%)
Nausea and vomiting (4%)
Muscle weakness (1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
unhealthy, 18-81 years
n = 1258
Health Status: unhealthy
Condition: migraine
Age Group: 18-81 years
Sex: M+F
Population Size: 1258
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
Other AEs: Dizziness, Fatigue...
Other AEs:
Dizziness (17%)
Fatigue (6%)
Paresthesia (9%)
Sedation (7%)
Nausea and vomiting (4%)
Muscle weakness (2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
unhealthy, 18-81 years
n = 654
Health Status: unhealthy
Condition: migraine
Age Group: 18-81 years
Sex: M+F
Population Size: 654
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
Other AEs: Dizziness, Fatigue...
Other AEs:
Dizziness (9%)
Fatigue (4%)
Paresthesia (3%)
Sedation (6%)
Nausea and vomiting (3%)
Muscle weakness (1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
120 mg 5 times / day single, oral
Highest studied dose
Dose: 120 mg, 5 times / day
Route: oral
Route: single
Dose: 120 mg, 5 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 1
Health Status: unhealthy
Condition: migraine
Age Group: adults
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
400 mg 1 times / day single, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: single
Dose: 400 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 70
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 70
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 991
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 991
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Disc. AE: Dizziness, Light headedness...
AEs leading to
discontinuation/dose reduction:
Dizziness (2.8%)
Light headedness (2.8%)
Somnolence (1.6%)
Sedation (1.6%)
Asthenia (0.7%)
Fatigue (0.7%)
Malaise (0.7%)
Weakness (0.7%)
Paresthesia (0.8%)
Hypoaesthesia (0.8%)
Nausea (0.7%)
Vomiting (0.7%)
Confusion (2.1%)
Delirium (2.1%)
Mental status changes (2.1%)
Disorientation (2.1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 1039
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 1039
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Disc. AE: Dizziness, Light headedness...
Other AEs: Confusion, Delirium...
AEs leading to
discontinuation/dose reduction:
Dizziness (4.2%)
Light headedness (4.2%)
Somnolence (1.2%)
Sedation (1.2%)
Asthenia (2.5%)
Fatigue (2.5%)
Malaise (2.5%)
Weakness (2.5%)
Paresthesia (1.8%)
Hypoaesthesia (1.8%)
Nausea (1.5%)
Vomiting (1.5%)
Confusion (1.4%)
Delirium (1.4%)
Mental status changes (1.4%)
Disorientation (1.4%)
Other AEs:
Confusion (1.4%)
Delirium (1.4%)
Mental status changes (1.4%)
Disorientation (1.4%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
AEs

AEs

AESignificanceDosePopulation
Muscle weakness 1%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
unhealthy, 18-81 years
n = 1265
Health Status: unhealthy
Condition: migraine
Age Group: 18-81 years
Sex: M+F
Population Size: 1265
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
Dizziness 15%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
unhealthy, 18-81 years
n = 1265
Health Status: unhealthy
Condition: migraine
Age Group: 18-81 years
Sex: M+F
Population Size: 1265
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
Nausea and vomiting 4%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
unhealthy, 18-81 years
n = 1265
Health Status: unhealthy
Condition: migraine
Age Group: 18-81 years
Sex: M+F
Population Size: 1265
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
Fatigue 5%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
unhealthy, 18-81 years
n = 1265
Health Status: unhealthy
Condition: migraine
Age Group: 18-81 years
Sex: M+F
Population Size: 1265
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
Sedation 6%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
unhealthy, 18-81 years
n = 1265
Health Status: unhealthy
Condition: migraine
Age Group: 18-81 years
Sex: M+F
Population Size: 1265
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
Paresthesia 7%
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
unhealthy, 18-81 years
n = 1265
Health Status: unhealthy
Condition: migraine
Age Group: 18-81 years
Sex: M+F
Population Size: 1265
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
Dizziness 17%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
unhealthy, 18-81 years
n = 1258
Health Status: unhealthy
Condition: migraine
Age Group: 18-81 years
Sex: M+F
Population Size: 1258
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
Muscle weakness 2%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
unhealthy, 18-81 years
n = 1258
Health Status: unhealthy
Condition: migraine
Age Group: 18-81 years
Sex: M+F
Population Size: 1258
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
Nausea and vomiting 4%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
unhealthy, 18-81 years
n = 1258
Health Status: unhealthy
Condition: migraine
Age Group: 18-81 years
Sex: M+F
Population Size: 1258
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
Fatigue 6%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
unhealthy, 18-81 years
n = 1258
Health Status: unhealthy
Condition: migraine
Age Group: 18-81 years
Sex: M+F
Population Size: 1258
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
Sedation 7%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
unhealthy, 18-81 years
n = 1258
Health Status: unhealthy
Condition: migraine
Age Group: 18-81 years
Sex: M+F
Population Size: 1258
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
Paresthesia 9%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
unhealthy, 18-81 years
n = 1258
Health Status: unhealthy
Condition: migraine
Age Group: 18-81 years
Sex: M+F
Population Size: 1258
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
Muscle weakness 1%
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
unhealthy, 18-81 years
n = 654
Health Status: unhealthy
Condition: migraine
Age Group: 18-81 years
Sex: M+F
Population Size: 654
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
Nausea and vomiting 3%
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
unhealthy, 18-81 years
n = 654
Health Status: unhealthy
Condition: migraine
Age Group: 18-81 years
Sex: M+F
Population Size: 654
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
Paresthesia 3%
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
unhealthy, 18-81 years
n = 654
Health Status: unhealthy
Condition: migraine
Age Group: 18-81 years
Sex: M+F
Population Size: 654
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
Fatigue 4%
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
unhealthy, 18-81 years
n = 654
Health Status: unhealthy
Condition: migraine
Age Group: 18-81 years
Sex: M+F
Population Size: 654
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
Sedation 6%
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
unhealthy, 18-81 years
n = 654
Health Status: unhealthy
Condition: migraine
Age Group: 18-81 years
Sex: M+F
Population Size: 654
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
Dizziness 9%
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
unhealthy, 18-81 years
n = 654
Health Status: unhealthy
Condition: migraine
Age Group: 18-81 years
Sex: M+F
Population Size: 654
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
Asthenia 0.7%
Disc. AE
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 991
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 991
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Fatigue 0.7%
Disc. AE
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 991
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 991
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Malaise 0.7%
Disc. AE
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 991
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 991
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Nausea 0.7%
Disc. AE
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 991
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 991
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Vomiting 0.7%
Disc. AE
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 991
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 991
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Weakness 0.7%
Disc. AE
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 991
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 991
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Hypoaesthesia 0.8%
Disc. AE
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 991
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 991
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Paresthesia 0.8%
Disc. AE
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 991
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 991
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Sedation 1.6%
Disc. AE
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 991
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 991
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Somnolence 1.6%
Disc. AE
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 991
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 991
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Confusion 2.1%
Disc. AE
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 991
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 991
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Delirium 2.1%
Disc. AE
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 991
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 991
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Disorientation 2.1%
Disc. AE
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 991
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 991
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Mental status changes 2.1%
Disc. AE
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 991
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 991
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Dizziness 2.8%
Disc. AE
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 991
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 991
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Light headedness 2.8%
Disc. AE
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 991
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 991
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Sedation 1.2%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 1039
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 1039
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Somnolence 1.2%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 1039
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 1039
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Confusion 1.4%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 1039
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 1039
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Delirium 1.4%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 1039
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 1039
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Disorientation 1.4%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 1039
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 1039
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Mental status changes 1.4%
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 1039
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 1039
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Confusion 1.4%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 1039
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 1039
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Delirium 1.4%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 1039
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 1039
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Disorientation 1.4%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 1039
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 1039
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Mental status changes 1.4%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 1039
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 1039
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Nausea 1.5%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 1039
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 1039
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Vomiting 1.5%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 1039
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 1039
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Hypoaesthesia 1.8%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 1039
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 1039
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Paresthesia 1.8%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 1039
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 1039
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Asthenia 2.5%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 1039
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 1039
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Fatigue 2.5%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 1039
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 1039
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Malaise 2.5%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 1039
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 1039
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Weakness 2.5%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 1039
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 1039
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Dizziness 4.2%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 1039
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 1039
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Light headedness 4.2%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
unhealthy, adults
n = 1039
Health Status: unhealthy
Condition: migraine
Age Group: adults
Sex: M+F
Population Size: 1039
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1709
inhibitor
1752

substrate
1010

inducer
383
inhibitor
1837

substrate
1193
inhibitor
1599

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1437

BCRP
691

OCT1
506

CYP1A2
1509

CYP2A6
704

CYP2B6
799

CYP2C8
901

CYP2C19
1463

CYP2E1
876

CYP3A
211

FMO3
3

MATE1
304

MATE2
261

OCT2
638

OAT1
595

OAT3
636

OATP1B1
781

OATP1B3
700
P-gp
1527

CYP1A2
1032

CYP2A6
523

CYP2B6
660

CYP2C8
688

CYP2C19
985

CYP2E1
648
CYP3A
126

CYP1A2
689
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
FMO3
3
 low
OAT1
599
 low
OAT3
638
 low
OATP1B1
796
 low
OATP1B3
709
 low
OCT2
639
 low
OCT1
523
 low
no (co-administration study)
Comment: "when administered with sumatriptan, no change in sumatriptan PK was observed; '""low potential of interactions"""
Page: 8, 18
CYP2A6
736
 no
CYP2B6
985
 no
CYP2C19
1537
 no
CYP2C8
955
 no
CYP2E1
964
 no
CYP1A2
1673
 no
no (co-administration study)
Comment: administered with caffeine, daily dosing of lasmiditan did not alter PK of caffeine
Page: 8.0
CYP1A2
1673
 no
no (co-administration study)
Comment: administered with caffeine, daily dosing of lasmiditan did not alter PK of caffeine
Page: 8.0
CYP2C9
1803
 no
no (co-administration study)
Comment: administered with tolbutamide, daily dosing of lasmiditan did not alter the PK of tolbutamide.
Page: 8.0
CYP2C9
1803
 no
no (co-administration study)
Comment: administered with tolbutamide, daily dosing of lasmiditan did not alter the PK of tolbutamide.
Page: 8.0
CYP3A
295
 no
no (co-administration study)
Comment: administered with midazolam, daily dosing of lasmiditan did not alter PK of midazolam
Page: 8.0
CYP3A
295
 no
no (co-administration study)
Comment: administered with midazolam, daily dosing of lasmiditan did not alter PK of midazolam
Page: 8.0
P-gp
1626
 yes [IC50 85 uM]
CYP2D6
1875
 yes [Ki 20.7 uM]
BCRP
765
 yes
MATE1
306
 yes
MATE2
261
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1032
 no
CYP2A6
523
 no
CYP2B6
660
 no
CYP2C19
985
 no
CYP2C8
688
 no
CYP2C9
1010
 no
CYP2D6
1193
 no
CYP2E1
648
 no
CYP3A4
1709
 no
P-gp
1527
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1632
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY113432
https://www.001chemical.com/chem/439239-90-4
AA Blocks
AA00DB3R
https://www.aablocks.com/goods/Goods/detail?id=AA00DB3R
AK Scientific, Inc. (AKSCI)
6063AB
http://www.aksci.com/item_detail.php?cat=6063AB
Aaron Chemicals
AR00DBVJ
http://www.aaronchem.com/439239-90-4
AbMole Bioscience
M10160
http://www.abmole.com/products/lasmiditan.html
AbMole Bioscience
M5214
http://www.abmole.com/products/lasmiditan.html
Achemo Scientific Limited
AC-105121
http://www.achemo.com/search/?Keyword=439239-90-4
Achemtek
0104-035885
http://www.achemtek.com/439239-90-4
Adooq BioScience
A14198
https://www.adooq.com/lasmiditan.html
Ambinter
Amb22233527
http://www.ambinter.com/reference/22233527
Angel Pharmatech
AG-11845
http://www.angelpharmatech.com/439239-90-4.html
Angene
AGN-PC-00CM98
http://www.angenechemical.com/productshow/AGN-PC-00CM98.html
ApexBio Technology
B1058
http://www.apexbt.com/lasmiditan.html
Ark Pharma Scientific Limited
A-1201
http://www.arkpharmtech.com/product/33152.html
Aurora Fine Chemicals LLC
A13.105.806
http://online.aurorafinechemicals.com/info?ID=A13.105.806
BioChemPartner
BCP04734
http://www.biochempartner.com/439239-90-4-BCP04734
BioCrick
BCC4077
http://www.biocrick.com/Lasmiditan-BCC4077.html
Boerchem
BC600589
http://www.boerchem.com/?product_43424.html
Chem Scene
CS-2032
http://www.chemscene.com/439239-90-4.html
Chemspace
CSSB00015188126
https://chem-space.com/CSSB00015188126
Clearsynth
CS-MM-09003
https://www.clearsynth.com/en/CSMM09003.html
DC Chemicals
DC7710
http://www.dcchemicals.com/product_show-Lasmiditan_COL_144_LY573144_.html
Excenen
EX-A1300
http://www.excenen.com/searchresultlist.php?id=439239-90-4
Excenen
EX-A1653
http://www.excenen.com/searchresultlist.php?id=439239-90-4
Lab Network
LN00188248
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00188248
Matrix Scientific
90054
https://www.matrixscientific.com/090054.html
MedChem Express
HY-14861
https://www.medchemexpress.com/lasmiditan.html
Molcore
MC113432
https://www.molcore.com/product/439239-90-4
Selleck Chemicals
S5064
http://www.selleckchem.com/products/lasmiditan.html
Smolecule
S532530
http://www.smolecule.com/products/s532530
Synblock Inc
SB19007
http://www.synblock.com/product/439239-90-4.html
THE BioTek
bt-272592
https://www.thebiotek.com/product/inhibitors/bt-272592
THE BioTek
bt-341446
https://www.thebiotek.com/product/others/bt-341446
abcr GmbH
AB479695
http://www.abcr.com/shop/en/AB479695
eNovation Chemicals
D501949
http://www.enovationchem.com/productDetails.asp?productID=D501949
eNovation Chemicals
Y1012792
https://www.enovationchem.com/ProductDetails.asp?ProductID=Y1012792
PubMed

PubMed

TitleDatePubMed
Patents

Patents

07423050
3
08044207
3
08697876
3
08748459
3
20050222206
3

Sample Use Guides

In Vitro Use Guide
Lasmiditan in vitro binding studies show a Ki value of 2.21 nM at the 5-HT(1F) serotonin receptor, compared with Ki values of 1043 nM and 1357 nM at the 5-HT(1B) and 5-HT(1D) receptors, respectively. Lasmiditan did not contract rabbit saphenous vein rings, a surrogate assay for human coronary artery constriction, at concentrations up to 100 uM.
Substance Class Chemical
Created
by admin
on Thu Jul 06 00:07:21 UTC 2023
Edited
by admin
on Thu Jul 06 00:07:21 UTC 2023
Record UNII
760I9WM792
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LASMIDITAN
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
Lasmiditan [WHO-DD]
Common Name English
2,4,6-Trifluoro-N-{6-[(1-methylpiperidine-4-yl)carbonyl]pyridin-2-yl}benzamide
Systematic Name English
COL-144
Code English
lasmiditan [INN]
Common Name English
LASMIDITAN [MI]
Common Name English
LASMIDITAN [USAN]
Common Name English
Classification Tree Code System Code
DEA NO. 2790
Created by admin on Thu Jul 06 00:07:21 UTC 2023 , Edited by admin on Thu Jul 06 00:07:21 UTC 2023
Code System Code Type Description
FDA UNII
760I9WM792
Created by admin on Thu Jul 06 00:07:21 UTC 2023 , Edited by admin on Thu Jul 06 00:07:21 UTC 2023
PRIMARY
INN
9176
Created by admin on Thu Jul 06 00:07:21 UTC 2023 , Edited by admin on Thu Jul 06 00:07:21 UTC 2023
PRIMARY
WIKIPEDIA
LASMIDITAN
Created by admin on Thu Jul 06 00:07:21 UTC 2023 , Edited by admin on Thu Jul 06 00:07:21 UTC 2023
PRIMARY
DAILYMED
760I9WM792
Created by admin on Thu Jul 06 00:07:21 UTC 2023 , Edited by admin on Thu Jul 06 00:07:21 UTC 2023
PRIMARY
PUBCHEM
11610526
Created by admin on Thu Jul 06 00:07:21 UTC 2023 , Edited by admin on Thu Jul 06 00:07:21 UTC 2023
PRIMARY
SMS_ID
100000172980
Created by admin on Thu Jul 06 00:07:21 UTC 2023 , Edited by admin on Thu Jul 06 00:07:21 UTC 2023
PRIMARY
ChEMBL
CHEMBL3039520
Created by admin on Thu Jul 06 00:07:21 UTC 2023 , Edited by admin on Thu Jul 06 00:07:21 UTC 2023
PRIMARY
EPA CompTox
DTXSID40469435
Created by admin on Thu Jul 06 00:07:21 UTC 2023 , Edited by admin on Thu Jul 06 00:07:21 UTC 2023
PRIMARY
MERCK INDEX
M12168
Created by admin on Thu Jul 06 00:07:21 UTC 2023 , Edited by admin on Thu Jul 06 00:07:21 UTC 2023
PRIMARY
DRUG BANK
DB11732
Created by admin on Thu Jul 06 00:07:21 UTC 2023 , Edited by admin on Thu Jul 06 00:07:21 UTC 2023
PRIMARY
DRUG CENTRAL
5351
Created by admin on Thu Jul 06 00:07:21 UTC 2023 , Edited by admin on Thu Jul 06 00:07:21 UTC 2023
PRIMARY
USAN
ZZ-66
Created by admin on Thu Jul 06 00:07:21 UTC 2023 , Edited by admin on Thu Jul 06 00:07:21 UTC 2023
PRIMARY
NCI_THESAURUS
C166996
Created by admin on Thu Jul 06 00:07:21 UTC 2023 , Edited by admin on Thu Jul 06 00:07:21 UTC 2023
PRIMARY
LACTMED
Lasmiditan
Created by admin on Thu Jul 06 00:07:21 UTC 2023 , Edited by admin on Thu Jul 06 00:07:21 UTC 2023
PRIMARY
RXCUI
2256930
Created by admin on Thu Jul 06 00:07:21 UTC 2023 , Edited by admin on Thu Jul 06 00:07:21 UTC 2023
PRIMARY
CAS
439239-90-4
Created by admin on Thu Jul 06 00:07:21 UTC 2023 , Edited by admin on Thu Jul 06 00:07:21 UTC 2023
PRIMARY
Related Record Type Details
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
In vitro studies showed that lasmiditan is a substrate of P-gp. However, lasmiditan is a BCS Class I drug and is unlikely to be affected by P-gp inhibitors.
Structure of LASMIDITAN
EXCRETED UNCHANGED
AMOUNT EXCRETED
URINE
ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2
TRANSPORTER -> INHIBITOR
Lasmiditan is an in-vitro inhibitor of P-gp and BCRP.
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> INHIBITOR
Lasmiditan is an in-vitro inhibitor of P-gp and BCRP.
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
The human plasma protein binding of lasmiditan is approximately 55% to 60% and independent of concentration between 15 and 500 ng/mL.
BINDING
Structure of LASMIDITAN SUCCINATE
SALT/SOLVATE -> PARENT
Structure of LASMIDITAN HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of LASMIDITAN
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966